



UCB celebrates the Grand Opening of a new facility in Shannon in presence of H.M. King Albert II, and appeals to build on Belgium's strong innovative capacities

Shannon, Ireland, October 10, 2007 at 1:00 PM (CET) – UCB welcomed today H.M. Albert II, King of Belgium, for the Grand Opening of a new facility.

The new manufacturing facility will enable the production of *fesoterodine*, a new drug to combat over-active bladder (incontinence) which has been developed by Schwarz Pharma, now part of the UCB Group, and is licensed exclusively to Pfizer.

Construction of the facility, along with other site upgrade projects will be completed by the end of this year and the plant will be in operation in the first quarter of 2008.

Dr Roch Doliveux, CEO and Chairman of the Executive Committee of UCB said: *"This new facility will enable the production of an important new drug here. With 815Mio EUR investment worldwide in R&D, in 2006 and the full integration of Schwarz Pharma, UCB is actively building the next generation biopharma leader.*

UCB today is large enough to advance an especially rich pipeline and to launch our new products to specialists first.

The recent launches of Neupro® and Xyzal® in the USA demonstrate the power to execute our projects"

UCB is taking advantage of the state visit of HM Albert II, King of Belgium to highlight the need for a common platform between Belgian universities and innovative industries, to make Belgium a leader in education, Research and Development.

Based on this success in Ireland and also in the USA, Dr. Roch Doliveux called for an increase of public research, university funding and improvements of education in Europe, especially Belgium to build on Belgium's strong innovative capacities especially in sectors as biopharma, ICT and nanotechnology.

Further information

Xavier Hormaechea

Public Affairs

T +32.2.559.9763

Xavier.hormaechea@ucb-group.com

About UCB

UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the I biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germany) is a member of UCB Group.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.